Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (not Scisparc Ltd.) covers the month of June 2017, with a report date of June 8, 2017. The registrant is a foreign private issuer based in Tel-Aviv, Israel, and files annual reports on Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate governance event rather than a financial statement.
Material Changes
The primary material change disclosed is the resignation of Micha Jesselson from his position as a member of the Board of Directors, effective June 7, 2017. The Company explicitly states that the resignation was not related to any disagreement with the Board regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the specific event of the director's resignation.
Key Facts for Investor Verification
- Micha Jesselson resigned from the Board of Directors on June 7, 2017.
- The resignation was voluntary and unrelated to any disagreement with the Company.
- The filing was signed by Josh Blacher, Chief Financial Officer, on June 8, 2017.
- No financial data or operational updates are included in this specific filing.